Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MAOB | P27338 | 7/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2721919 | 0.81 | KDM4E (0.52) | KDM4EALDH1A1MAOBTHRATHRB | |
| SCHEMBL2132602 | 0.79 | KDM4E (0.36) | KDM4EALDH1A1MAOBKMT2AMEN1 | |
| SCHEMBL2134426 | 0.76 | PDK2 (0.47) | KDM4EALDH1A1MAOBTHRATHRB | |
| SCHEMBL13652565 | 0.74 | CA12 (0.47) | KDM4EALDH1A1THRATHRBKMT2A | |
| SCHEMBL2133555 | 0.72 | L3MBTL1 (0.44) | KDM4EALDH1A1MAOBTHRATHRB | |
| SCHEMBL22483601 | 0.71 | CA12 (0.47) | KDM4EALDH1A1MAOBKMT2AMAPT | |
| SCHEMBL2721920 | 0.71 | L3MBTL1 (0.49) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2134422 | 0.71 | PPARG (0.40) | KDM4EALDH1A1KMT2AMEN1PPARA | |
| SCHEMBL31111406 | 0.70 | L3MBTL1 (0.50) | KDM4EALDH1A1THRATHRBMAPT | |
| SCHEMBL2133616 | 0.69 | BRD4 (0.55) | MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445892-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-20120101136-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1- PHOSPHATE RECEPTOR AGONISTS | GLAXO GROUP LIMITED | 2012-04-26 | — | — | US | disclosed |
| WO-2010148650-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101136-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1- PHOSPHATE RECEPTOR AGONISTS | S1PR1, S1PR5, S1PR3 | KDM4E 3897/4885ALDH1A1 2923/4885MAOB 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.